EQRx to Participate in Cowen’s 42nd Annual Health Care Conference
EQRx, a pharmaceutical company focused on providing innovative medicines at lower prices, will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on March 9, 2022, at 12:50 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
EQRx, a pharmaceutical company focused on providing innovative medicines at lower prices, will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on March 9, 2022, at 12:50 p.m. ET. Investors and interested parties can access a live and archived webcast of the chat via EQRx’s website in the Events & Presentations section. Launched in January 2020, EQRx collaborates with stakeholders to deliver cost-effective, patent-protected medicines, catering to high-cost drug categories.
Details
News Market Reaction – EQRX
The recorded move for EQRX in the trading session of this news was -4.76%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced that management will participate in a fireside chat at Cowen’s 42nd Annual Health Care Conference on Wednesday, March 9, 2022 at 12:50 p.m. ET.
A live and archived webcast of the fireside chat will be available by visiting the Events & Presentations section of EQRx’s website at investors.eqrx.com.
About EQRx
EQRx is a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices. Launched in January 2020, EQRx is purpose-built, at scale, with a growing catalog of medicines in development in high-cost drug categories and emerging partnerships with leading payers and providers. Leveraging cutting-edge science and technology and strategic partnerships with stakeholders from across the healthcare system, EQRx aims to provide innovative, patent-protected medicines more efficiently and cost-effectively than ever before. To learn more, visit www.eqrx.com and follow us on social media: Twitter: @EQRxInc, LinkedIn, Instagram: @eqrxinc.
EQRx™ and Remaking Medicine™ are trademarks of EQRx.
EQRx Contacts:
Media:
Dan Budwick
1AB
dan@1abmedia.com
Investors:
investors@eqrx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.